Pfizer Inc. (PFE)
Pfizer Inc. is a global pharmaceutical company known for its research and development of innovative medicines and vaccines. Founded in 1849, it has a diverse portfolio that includes treatments for various medical conditions, and it played a key role in developing one of the first COVID-19 vaccines. Pfizer operates in multiple healthcare sectors, including biopharmaceuticals, oncology, and immunology.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 2, 2025 | $0.43 | 2025-07-25 | 2025-07-25 |
| June 13, 2025 | $0.43 | 2025-05-09 | 2025-05-09 |
| March 7, 2025 | $0.43 | 2025-01-24 | 2025-01-24 |
| December 2, 2024 | $0.42 | 2024-11-08 | 2024-11-08 |
| September 3, 2024 | $0.42 | 2024-07-26 | 2024-07-26 |
Dividends Summary
- Pfizer Inc. has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 35 days ago, on September 2, 2025
- The highest dividend payed out to investors during this period was $0.43 per share
- The average dividend paid during this period was $0.30 per share.
Company News
The Q3 earnings season is expected to show solid corporate performance, driven by AI investments, resilient economic growth, and potential low-teens earnings growth for the S&P 500, with the Magnificent Seven tech companies leading the way.
Pfizer is experiencing challenges with declining COVID vaccine sales and potential patent expirations, but recent government negotiations and strategic acquisitions offer potential for future growth. The stock has been struggling but shows signs of potential recovery.
President Trump signed an Executive Order on AI for childhood cancer research, launched TrumpRx for prescription drug pricing, addressed military leadership, and made progress on Middle East peace negotiations while maintaining strong economic performance.
Pfizer agreed with the Trump Administration to lower prescription drug prices for U.S. patients, offering significant discounts on several medications and committing to invest $70 billion in U.S. research and development.
During periods of heightened volatility, low-beta stocks can provide a valuable layer of defense and a more balanced risk profile. Northrop Grumman, Pfizer, and Kimberly-Clark have recently seen positive earnings estimate revisions, landing them in favorable Zacks Ranks.
